Results 61 to 70 of about 636 (113)

The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. [PDF]

Cancer Immunol Immunother, 2018
Anichini A, Tassi E, Grazia G, Mortarini R.   +3 more
europepmc   +1 more source

[Prevalence and risk factors for methicillin-resistant Staphylococcus aureus infection in children]. [PDF]

Rev Esp Quimioter
Marín Oliván P, Ferrando Monleón S, Bretón-Martínez JR, Piolatti Luna A, Hernández Monleón I, Fuertes Latasa C, Navarro Ortega D, Colomina Rodríguez J.   +7 more
europepmc   +1 more source

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. [PDF]

Cancer Immunol Immunother, 2015
Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P.   +5 more
europepmc   +1 more source

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? [PDF]

Cancer Immunol Immunother, 2015
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M.   +6 more
europepmc   +1 more source

Cholesterol metabolites and tumor microenvironment: the road towards clinical translation. [PDF]

Cancer Immunol Immunother, 2016
Raccosta L, Fontana R, Corna G, Maggioni D, Moresco M, Russo V.   +5 more
europepmc   +1 more source

Medicina Balear 2016, vol. 31, n. 1 [PDF]

Medicina Balear, òrgan de la Reial Acadèmia de Medicina de les Illes Balears, publica en català, castellà o anglès treballs originals, articles de revisió, cartes al director i altres escrits d'interès relacionats amb les ciències de la salut i presta ...
Reial Acadèmia de Medicina de les Illes Balears
core  

T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. [PDF]

Cancer Immunol Immunother, 2018
Kallikourdis M.
europepmc   +1 more source

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. [PDF]

Cancer Immunol Immunother, 2015
Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P.   +5 more
europepmc   +1 more source

Overcoming the toxicity hurdles of genetically targeted T cells. [PDF]

Cancer Immunol Immunother, 2015
Casucci M, Hawkins RE, Dotti G, Bondanza A.   +3 more
europepmc   +1 more source

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. [PDF]

Cancer Immunol Immunother, 2018
Petitprez F, Vano YA, Becht E, Giraldo NA, de Reyniès A, Sautès-Fridman C, Fridman WH.   +6 more
europepmc   +1 more source